

Irina U Agoulnik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9521710/publications.pdf>

Version: 2024-02-01

59
papers

2,517
citations

218677

26
h-index

197818

49
g-index

60
all docs

60
docs citations

60
times ranked

3065
citing authors

#	ARTICLE	IF	CITATIONS
1	INPP4B protects from metabolic syndrome and associated disorders. <i>Communications Biology</i> , 2021, 4, 416.	4.4	10
2	Inhibition of base excision repair by natamycin suppresses prostate cancer cell proliferation. <i>Biochimie</i> , 2020, 168, 241-250.	2.6	18
3	Deletion of inositol polyphosphate 4-phosphatase type-II B affects spermatogenesis in mice. <i>PLoS ONE</i> , 2020, 15, e0233163.	2.5	7
4	Androgen Receptor and Poly(ADP-ribose) Glycohydrolase Inhibition Increases Efficiency of Androgen Ablation in Prostate Cancer Cells. <i>Scientific Reports</i> , 2020, 10, 3836.	3.3	6
5	Oxidative DNA Damage Modulates DNA Methylation Pattern in Human Breast Cancer 1 (BRCA1) Gene via the Crosstalk between DNA Polymerase β and a de novo DNA Methyltransferase. <i>Cells</i> , 2020, 9, 225.	4.1	18
6	Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. <i>FASEB Journal</i> , 2019, 33, 12435-12446.	0.5	18
7	Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. <i>Oncogene</i> , 2019, 38, 1121-1135.	5.9	10
8	SAT-035 Small Molecule Allosteric Agonist of Relaxin Receptor ML290 Demonstrates Antifibrotic Properties in Liver Fibrosis. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
9	SAT-326 INPP4B Suppresses Prostate Inflammation And Protects Mice Fed With High-fat Diet From The Development Of Prostate Intraepithelial Neoplasia. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
10	Techniques for Evaluation of AR Transcriptional Output and Recruitment to DNA. <i>Methods in Molecular Biology</i> , 2018, 1786, 219-236.	0.9	3
11	Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 79-92.	5.5	9
12	Multiferroic core-shell magnetoelectric nanoparticles as NMR sensitive nanoprobe for cancer cell detection. <i>Scientific Reports</i> , 2017, 7, 1610.	3.3	21
13	Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1. <i>British Journal of Pharmacology</i> , 2017, 174, 977-989.	5.4	21
14	Human Relaxin Receptor Is Fully Functional in Humanized Mice and Is Activated by Small Molecule Agonist ML290. <i>Journal of the Endocrine Society</i> , 2017, 1, 712-725.	0.2	18
15	Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2016, 22, 3937-3949.	7.0	24
16	Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists. <i>Biochemistry</i> , 2016, 55, 1772-1783.	2.5	22
17	INPP4B is an oncogenic regulator in human colon cancer. <i>Oncogene</i> , 2016, 35, 3049-3061.	5.9	52
18	Long-Lasting Consequences of Testosterone Exposure. <i>Endocrinology</i> , 2015, 156, 3488-3489.	2.8	0

#	ARTICLE	IF	CITATIONS
19	Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290. <i>Frontiers in Endocrinology</i> , 2015, 6, 128.	3.5	19
20	Base Excision Repair of Chemotherapeutically-Induced Alkylated DNA Damage Predominantly Causes Contractions of Expanded GAA Repeats Associated with Friedreich's Ataxia. <i>PLoS ONE</i> , 2014, 9, e93464.	2.5	16
21	INPP4B suppresses prostate cancer cell invasion. <i>Cell Communication and Signaling</i> , 2014, 12, 61.	6.5	36
22	Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1. <i>Nature Communications</i> , 2013, 4, 1953.	12.8	54
23	Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 763-772.	2.8	43
24	Determinants of the tumor suppressor INPP4B protein and lipid phosphatase activities. <i>Biochemical and Biophysical Research Communications</i> , 2013, 440, 277-282.	2.1	18
25	Identification of Small-Molecule Agonists of Human Relaxin Family Receptor 1 (RXFP1) by Using a Homogenous Cell-Based cAMP Assay. <i>Journal of Biomolecular Screening</i> , 2013, 18, 670-677.	2.6	27
26	Reduced Androgen Receptor Expression Accelerates the Onset of ERBB2 Induced Breast Tumors in Female Mice. <i>PLoS ONE</i> , 2013, 8, e60455.	2.5	11
27	Roles of Androgen Receptor Coregulators and Cell Signaling in the Regulation of Androgen-Responsive Genes. , 2013, , 1-11.		0
28	Androgen receptor footprint on the way to prostate cancer progression. <i>World Journal of Urology</i> , 2012, 30, 279-285.	2.2	21
29	Decreased Expression and Androgen Regulation of the Tumor Suppressor Gene INPP4B in Prostate Cancer. <i>Cancer Research</i> , 2011, 71, 572-582.	0.9	126
30	INPP4B: the New Kid on the PI3K Block. <i>Oncotarget</i> , 2011, 2, 321-328.	1.8	97
31	Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. <i>Endocrine-Related Cancer</i> , 2010, 17, 1021-1033.	3.1	63
32	GEMS (Gene Expression MetaSignatures), a Web Resource for Querying Meta-Analysis of Expression Microarray Datasets: Dihydrotestosterone in LNCaP Cells. , 2010, , P3-65-P3-65.		0
33	Relaxin/RXFP1 Signaling in Prostate Cancer Progression. <i>Annals of the New York Academy of Sciences</i> , 2009, 1160, 379-380.	3.8	22
34	Relaxin Signaling in Uterine Fibroids. <i>Annals of the New York Academy of Sciences</i> , 2009, 1160, 374-378.	3.8	6
35	Coactivator selective regulation of androgen receptor activity. <i>Steroids</i> , 2009, 74, 669-674.	1.8	60
36	Coregulators and the Regulation of Androgen Receptor Action in Prostate Cancer. , 2009, , 315-340.		3

#	ARTICLE	IF	CITATIONS
37	Target Gene-Specific Regulation of Androgen Receptor Activity by p42/p44 Mitogen-Activated Protein Kinase. <i>Molecular Endocrinology</i> , 2008, 22, 2420-2432.	3.7	30
38	Androgen Receptor Coactivators and Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 617, 245-255.	1.6	38
39	Androgen Receptor Coactivators in Prostate Cancer. , 2008, , 281-300.		0
40	Relaxin Promotes Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2007, 13, 1695-1702.	7.0	101
41	Developmental Expression and Gene Regulation of Insulin-like 3 Receptor RXFP2 in Mouse Male Reproductive Organs1. <i>Biology of Reproduction</i> , 2007, 77, 671-680.	2.7	47
42	Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. <i>Journal of Cellular Biochemistry</i> , 2006, 98, 770-788.	2.6	94
43	Androgen receptor action in hormone-dependent and recurrent prostate cancer. <i>Journal of Cellular Biochemistry</i> , 2006, 99, 362-372.	2.6	117
44	The role of relaxin in endometrial cancer. <i>Cancer Biology and Therapy</i> , 2006, 5, 71-77.	3.4	51
45	Androgens Modulate Expression of Transcription Intermediary Factor 2, an Androgen Receptor Coactivator whose Expression Level Correlates with Early Biochemical Recurrence in Prostate Cancer. <i>Cancer Research</i> , 2006, 66, 10594-10602.	0.9	162
46	Role of SRC-1 in the Promotion of Prostate Cancer Cell Growth and Tumor Progression. <i>Cancer Research</i> , 2005, 65, 7959-7967.	0.9	186
47	Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. <i>Prostate</i> , 2005, 64, 362-372.	2.3	47
48	Pim-2 upregulation: Biological implications associated with disease progression and perineural invasion in prostate cancer. <i>Prostate</i> , 2005, 65, 276-286.	2.3	59
49	A Germline Variation in the Progesterone Receptor Gene Increases Transcriptional Activity and May Modify Ovarian Cancer Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 6340-6347.	3.6	76
50	Repressors of Androgen and Progesterone Receptor Action. <i>Journal of Biological Chemistry</i> , 2003, 278, 31136-31148.	3.4	118
51	Biodistribution and pharmacokinetics of aerosol and intravenously administered dnaâ€“polyethyleneimine complexes: optimization of pulmonary delivery and retention. <i>Molecular Therapy</i> , 2003, 8, 249-254.	8.2	72
52	A Novel Androgen Receptor Mutant, A748T, Exhibits Hormone Concentration-Dependent Defects in Nuclear Accumulation and Activity Despite Normal Hormone-Binding Affinity. <i>Molecular Endocrinology</i> , 2002, 16, 2692-2705.	3.7	19
53	A transgenic insertion upstream of Sox9 is associated with dominant XX sex reversal in the mouse. <i>Nature Genetics</i> , 2000, 26, 490-494.	21.4	338
54	Cloning, expression analysis and chromosomal localization of the human nuclear receptor gene GCNF. <i>FEBS Letters</i> , 1998, 424, 73-78.	2.8	38

#	ARTICLE	IF	CITATIONS
55	In VivoGene Therapy of Ovarian Cancer by Adenovirus-Mediated Thymidine Kinase Gene Transduction and Ganciclovir Administration. Gynecologic Oncology, 1996, 61, 175-179.	1.4	41
56	Therapeutic potentials of small molecular weight allosteric agonist of relaxin receptor. Endocrine Abstracts, 0, , .	0.0	0
57	Regulation of steroid receptor signalling by tumor suppressor INPP4B. Endocrine Abstracts, 0, , .	0.0	0
58	Small molecule allosteric agonist of relaxin receptor ML290 demonstrates antifibrotic properties in liver fibrosis. Endocrine Abstracts, 0, , .	0.0	0
59	Expression pattern and the roles of phosphatidylinositol phosphatases in testis. Biology of Reproduction, 0, , .	2.7	0